180 Life Sciences announced the publication of a review entitled ‘Dupuytren’s disease: a localized and accessible human fibrotic disorder’ in the journal Trends in Molecular Medicine. In the article, the authors at the University of Oxford, led by Professor Jagdeep Nanchahal, chairman of the medical advisory board of 180 Life Sciences, describe the biology of Dupuytren’s disease, to which they have made important contributions. The authors describe the genetics of this highly heritable disorder, the cellular mechanisms, the intercellular interactions and the key role of low-grade chronic inflammation in the pathogenesis of the disorder. One of the most important findings is that the mechanisms underlying the development of fibrosis in the hand are very similar to those in internal organs such as the lung in idiopathic pulmonary fibrosis. Dr. James Woody, CEO of 180 Life Sciences, stated, "Treatment of early-stage Dupuytren’s disease represents a huge unmet medical need, and at 180 Life Sciences we are delighted to be advancing the pioneering work of Prof. Nanchahal and his team who are developing the use of anti-TNF hopefully for the benefit of the millions of patients affected by early-stage Dupuytren’s disease, for which there is no approved treatment."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ATNF:
- 180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
- 180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease
- 180 Life Sciences CEO says priorities continue to be clinical programs
- 180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
- 180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules